COVID-19

News

Gilead finally breaks its silence on remdesivir’s price

After weeks of speculation, Gilead Sciences has revealed its pricing plans for coronavirus drug remdesivir – and the rationale behind its decision.

Views & Analysis

The real impact of COVID-19 on emerging markets

When COVID-19 began to spread uncontrollably, numbers of confirmed cases initially grew most quickly in developed economies across China, Europe and then the US.

News

COVID-19 drug remdesivir recommended for EU approval

The EMA’s human medicines committee (CHMP) has recommended granting a conditional marketing authorisation to Gilead’s COVID-19 treatment remdesivir – making it the first drug of its kind to be g

Views & Analysis

Coronavirus pharma news roundup - 26/06/20

As COVID-19 drugs vie for approval, we highlight the top pharma R&D, digital and market access news for coronavirus from the past week.

Views & Analysis

COVID-19 and cancer: can pharma stymie the pandemic’s impact...

The COVID-19 pandemic may lead to increased cases of cancer mortality – what can biopharma companies do to help lessen the impact?

News

Pediatrician makes vaccination to small boy

Safety fears deter parents from clinic visits for vaccinatio...

Parents’ willingness to vaccinate children has been boosted by the COVID-19 pandemic, but safety fears mean few are willing to take their child to a medical centre to receive jabs, accordin

Gilead finally breaks its silence on remdesivir’s price

The real impact of COVID-19 on emerging markets

COVID-19 drug remdesivir recommended for EU approval

Coronavirus pharma news roundup - 26/06/20

COVID-19 and cancer: can pharma stymie the pandemic’s impact...

Safety fears deter parents from clinic visits for vaccinatio...

CEPI steps in to fund Moderna's pandemic flu jab

How to meet your physicians where they are online

COVID-19

Editor's Picks